Citius Pharma FY2023 net loss $32.5M; Mino-Lok Phase 3 enrollment done, topline Q2 2024

Citius Pharmaceuticals, Inc.

Net loss $32.5M ($0.22/share) for FY ended Sep 30, 2023; cash $26.5M, runway through Aug 2024.
Mino-Lok Phase 3 completed (241 patients, 109 events); topline results expected Q2 2024.
LYMPHIR BLA resubmission on track for early 2024 after July 2023 CRL; PDUFA later in 2024.
Halo-Lido Phase 2b completed; end-of-Phase 2 meeting with FDA planned early 2024.
Oncology subsidiary to merge with TenX Keane Acquisition (TENKU) to form publicly listed Citius Oncology.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Citius Pharmaceuticals, Inc. reported fiscal full year ended September 30, 2023 results: net income Net loss was $32.5 million, or ($0.22) per share, EPS ($0.22) per share.

Period: fiscal full year ended September 30, 2023
Net income: Net loss was $32.5 million, or ($0.22) per share
EPS: ($0.22) per share
Result: reported results

Exact text from the filing

Net loss was $32.5 million, or ($0.22) per share for the full year ended September 30, 2023

View on SEC.gov

Browse all earnings releases →

Citius Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-000247

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.